Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 2Endocrine 2Sarcoma 1Lymphoid 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 38Breast Neoplasms, Male 6Stomach Neoplasms 4Lung Neoplasms 4Salivary Gland Neoplasms 3Pancreatic Neoplasms 3Ovarian Neoplasms 3Neuroendocrine Tumors 3Esophageal Neoplasms 3Colonic Neoplasms 3Carcinoma, Transitional Cell 3Carcinoma, Renal Cell 3Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Tongue Neoplasms 2Thyroid Neoplasms 2Sarcoma 2Rectal Neoplasms 2Prostatic Neoplasms 2Oropharyngeal Neoplasms 2Neoplasm Metastasis 2Nasopharyngeal Neoplasms 2Mouth Neoplasms 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Colorectal Neoplasms 2Vaginal Neoplasms 1Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1

Interventions

tivozanib 1atezolizumab 1Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Neuroendocrine × Fluorodeoxyglucose F18 × Breast × Clear all
NCT05396118 2024-05-14

Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer Patients

Rigshospitalet, Denmark

Phase 2 Unknown
15 enrolled
BreastEndocrineLymphoidNETSarcoma

Breast Neoplasms, Lymphoma, Sarcoma, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡